FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to the pharmaceutical industry, in particular to a stable pharmaceutical composition based on etanercept. Said stable pharmaceutical composition comprises etanercept, phosphate-citrate buffer and glycine as anti-aggregation agent taken in a certain ratio.
EFFECT: above pharmaceutical composition has improved stability and aggregation resistance.
10 cl, 6 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE LIQUID PHARMACEUTICAL PREPARATIONS OF FUSED PROTEIN TNFR: Fc | 2012 |
|
RU2614257C2 |
| LIQUID COMPOSITION OF POLYPEPTIDES CONTAINING FC DOMAIN OF IMMUNOGLOBULIN | 2011 |
|
RU2600847C2 |
| STABLE LIQUID ETANERCEPT COMPOSITION | 2012 |
|
RU2575619C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING BIOPHARMACEUTICAL DRUG | 2011 |
|
RU2587056C2 |
| ALTERNATIVE COMPOSITIONS FOR TNFR:FC CHIMERICAL POLYPEPTIDES | 2014 |
|
RU2663727C2 |
| LIQUID FORMULATIONS FOR LONG-ACTING ERYTHROPOIETIN CONJUGATE | 2011 |
|
RU2682720C2 |
| STABLE PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2736830C2 |
| LIQUID FORMULATION OF LONG-ACTING INSULINOTROPIC PEPTIDE CONJUGATE | 2013 |
|
RU2671576C2 |
| STABLE COMPOSITIONS OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAIN AND THEIR USE | 2014 |
|
RU2773172C2 |
| LIQUID FORMULATIONS FOR LONG-ACTING CONJUGATE OF G-CSF | 2011 |
|
RU2519031C1 |
